Journal of the College of Physicians and Surgeons Pakistan
ISSN: 1022-386X (PRINT)
ISSN: 1681-7168 (ONLINE)
Affiliations
doi: 10.29271/jcpsp.2020.04.389ABSTRACT
Objective: To investigate factors influencing pathological response to neoadjuvant chemotherapy (NAC) in operable primary breast cancer.
Study Design: Descriptive study.
Place and Duration of Study: Breast Center, Shunyi District Health Care Hospital for Women and Children of Beijing, Beijing 101300, P.R. China, from January 2009 to December 2017.
Methodology: Two hundred and sixty-one operable primary invasive breast cancer patients treated with NAC were included in this observational study. Pathological complete response (pCR) was defined as no residual invasive disease in either the breast or the axillary lymph nodes, with non-invasive breast residuals permitted (ypT0/is ypN0). Factors affecting pCR were subjected to univariate and multivariate analysis.
Results: Seventy-six patients (29.1%) achieved pCR after NAC. Tumor size, histological grade, status of estrogen receptor (ER) and progesterone receptor (PgR), expression of human epidermal growth factor receptor 2 (HER2) and Ki67, axillary lymph node status, and chemotherapy regimen were all significantly associated with pCR in univariate analysis (all p<0.05). In multivariate analysis, high histological grade, negative HR status and lymph nodes, positive HER2 status, and taxane-based regimens were independent predictive factors of pCR. Patients with HER2-positive tumors were more sensitive to NAC regimen including trastuzumab.
Conclusion: In this study, breast cancer patients with high histological grade, negative HR status and lymph nodes, positive HER2 status, as well as taxane-based regimens were significantly associated with achieving pCR with NAC.
Key Words: Breast neoplasms, Neoadjuvant therapy, Surgery, Pathology.
INTRODUCTION
Neoadjuvant chemotherapy (NAC) is an equivalent option to adjuvant chemotherapy by clinical trials in terms of breast cancer survival. Additionally, it provides a chance to evaluate the response of breast tumors to chemotherapy regimen. Thus, NAC has several advantages. These include initiation of systematic treatment as soon as possible towards primary and potential metastases lesions; reduction of tumor size to improve the chance of breast conserving surgery; identification and termination of ineffective treatment, and replacement of more effective therapy timely; providing platform for research through clinical monitoring, as well as obtaining blood and tissue specimens at different times during neoadjuvant therapy.1,2
NSABP B-18 trial indicated that patients whose tumors achieved pathological complete response (pCR) had a better 5-year DFS, RFS, and survival.3 It is a surrogate end-point for survival, and now an approved end-point in accelerated approval of novel chemo-therapeutic agents.
Several clinical and pathological factors are known to affect pCR; for instance, tumor size, histological grade, status of ER and PgR, and expression of HER2 and Ki67. It is widely accepted that tumors with subtypes of HER2-positive and triple negative (TN) show higher pCR rates, while tumors with luminal A subtype are the least likely to achieve pCR.4,5 As obesity is recognized a risk factor of breast cancer, higher BMI may also be negatively associated with pCR; however, this is still controversial.6,7
Recently, there is an increasing focus on peripheral inflammatory indicators, such as neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Studies show lower NLR and/or lower PLR might be independent predictor of pCR either alone or combined.8 A study conducted in South China suggested that NLR<2.06 was associated with desirable pCR rate, and lower NLR was an independent prognostic predictor.9 However, the predictive value of inflammatory indicators has not been analysed along with other clinicopathological factors in study among breast cancer patients in North China. In this study, the objective was to investigate the factors predicting pCR in primary breast cancer patients receiving preoperative chemotherapy, aimed to provide basis for response evaluation of NAC.
Table I: Patient characteristics.
|
N=261 |
% |
Age (year) ≤50 >50 |
128 133 |
49.0 51.0 |
BMI Normal/low weight Overweight Obesity |
77 109 75 |
29.5 41.8 28.7 |
Menopause Yes No |
124 137 |
47.5 52.5 |
Family history of malignancy Yes No |
41 220 |
15.7 84.3 |
Tumor size (cm) ≤2 >2 |
61 200 |
23.4 76.6 |
Pathological type IDC Other |
237 24 |
90.8 9.2 |
Grade Ⅰ+Ⅱ Ⅲ Unknown |
188 60 13 |
72.0 23.0 5.0 |
ER Negative Positive |
91 170 |
34.9 65.1 |
PgR Negative Positive |
108 153 |
41.4 58.6 |
HER2 Negative Positive Unknown |
150 104 7 |
39.8 2.7 |
Ki67 Low expression High expression Unknown |
44 200 17 |
16.9 76.6 6.5 |
Lymph nodes Negative Positive Unknown |
96 150 15 |
36.8 57.5 5.7 |
Chemotherapy cycles 4~ 6~ 8~ |
55 70 136 |
21.1 26.8 52.1 |
Chemotherapy regimens Anthracycline-based Taxane-based Combination of anthracycline and taxane |
44 106 111 |
16.9 40.6 42.5 |
Baseline NLR <2.1 ≥2.1 |
130 131 |
49.8 50.2 |
Baseline PLR <150 ≥150 |
161 100 |
61.7 38.3 |
Molecular subtype Triple negative HER2-positive (any HR status) Luminal |
44 104 113 |
16.9 39.8 43.3 |
Pathological response pCR Non-pCR |
76 185 |
29.1 70.9 |
Table II: Association of baseline clinical characteristics with pathological response.
|
pCR (n=76, %) |
non-pCR (n=185, %) |
p-value |
Age (year) ≤50 >50 |
33 (43.4) 43 (56.6) |
95 (51.4) 90 (48.6) |
0.244 |
BMI Normal/low weight Overweight Obesity |
29 (38.2) 25 (32.9) 22 (28.9) |
48 (25.9) 84 (45.4) 53 (28.6) |
0.093 |
Menopause Yes No |
39 (51.3) 37 (48.7) |
85 (45.9) 100 (54.1) |
0.430 |
Family history of malignancy Yes No |
12 (15.8) 64 (84.2) |
29 (15.7) 156 (84.3) |
0.982 |
Tumor size (cm) ≤2 >2 |
25 (32.9) 51 (67.1) |
36 (19.5) 149 (80.5) |
0.020 |
Pathological type IDC Other |
68 (89.5) 8 (10.5) |
169 (91.4) 16 (8.6) |
0.633 |
Grade Ⅰ+Ⅱ Ⅲ |
38 (53.5) 33 (46.5) |
150 (84.7) 27 (15.3) |
<0.001 |
ER Negative Positive |
44 (57.9) 32 (42.1) |
47 (25.4) 138 (74.6) |
<0.001 |
PgR Negative Positive |
50 (65.8) 26 (34.2) |
58 (31.4) 127 (68.6) |
<0.001 |
HER2 Negative Positive |
34 (45.3) 41 (54.7) |
116 (64.8) 63 (35.2) |
0.004 |
Ki67 Low expression High expression |
6 (8.2) 67 (91.8) |
38 (22.2) 133 (77.8) |
0.009 |
Lymph nodes Negative Positive |
42 (57.5) 31 (42.5) |
54 (31.2) 119 (68.8) |
<0.001 |
Chemotherapy cycle 4~ 6~ 8~ |
12 (15.8) 23 (30.3) 41 (53.9) |
43 (23.2) 47 (25.4) 95 (51.4) |
0.375 |
Chemotherapy regimens Anthracycline-based Taxane-based Combination of anthracycline and taxane |
8 (10.5) 53 (69.7) 15 (19.7) |
36 (19.5) 53 (28.6) 96 (51.9) |
<0.001 |
Baseline NLR <2.1 ≥2.1 |
39 (51.3) 37 (48.7) |
91 (49.2) 94 (50.8) |
0.755 |
Baseline PLR <150 ≥150 |
40 (52.6) 36 (47.4) |
121 (65.4) 64 (34.6) |
0.054 |
METHODOLOGY
It was a descriptive study conducted at the Department of Breast Center, Shunyi District Health Care Hospital for Women and Children of Beijing. The study was approved by the Research and Ethical Committee of the Hospital. From January 2009 to December 2017, a total of 303 consecutive women who had operable primary invasive breast cancer were treated with NAC at the Breast Center. All breast cancer cases were diagnosed by core needle biopsy (CNB) with a 16-gauge needle. Excluding those who received less than 4 cycles of treatment, 261 patients who had completed at least 4 cycles of NAC were enrolled in analysis ultimately.
Table Ⅲ: Multivariate unconditional logistic regression model for predicting pCR.
|
β |
OR (95%CI) |
p-value |
Grade (Ⅲ versus Ⅰ+Ⅱ) |
0.964 |
2.62 (1.21-5.70) |
0.015 |
HR (negative versus positive) |
0.864 |
2.37 (1.14-4.94) |
0.021 |
Lymph nodes (negative versus positive) |
0.824 |
2.28 (1.13-4.62) |
0.022 |
HER2 (positive versus negative) |
0.761 |
2.14 (1.04-4.39) |
0.038 |
Chemotherapy regimens (taxane-based versus combination) |
1.274 |
3.58 (1.61-7.94) |
0.002 |
Demographic characteristics, and clinicopathological data were obtained from in-patient medical record. Overweight was defined as a BMI of 24.0 to 27.9 and obesity as a BMI of 28.0 or higher according to Chinese standard.10 Ultrasound examination was routinely conducted before CNB, and tumor size was measured. ER, PgR, HER2 status and Ki67 index were determined by immunohistochemistry (IHC), and tumors with HER2 score 2+ were additionally evaluated by FISH, according to guidelines and expert consensus of China.11,12 ER or PgR was considered positive when ≥1% of tumor cells showed positive nuclear staining. The cutoff value of high expression for Ki67 was ≥20%, as was discussed and in favour of by majority of the panellists on the 13th St. Gallen International Breast Cancer Conference.13
Axillary lymph node status at baseline was evaluated through 2 steps prior to the beginning of NAC: firstly, ultrasound examination was used to scan the armpit area, and CNB or fine needle aspiration (FNA) was applied, if abnormally morphological lymph node was found; then, patients with negative result in CNB or FNA, as well as those without abnormally morphological lymph node in ultrasound examination, were recommended to consider sentinel lymph node biopsy (SLNB). Patients with positive result in CNB, FNA, or SLNB, and those rejected SLNB, would accept axillary lymph node dissection in surgery. Meanwhile, those without axillary lymph node involvement in SLNB would avoid dissection.
The cutoff values of NLR and PLR were determined considering median and the boundary value proposed in literature.9 Pathological complete response (pCR) was defined as no residual invasive disease in either the breast or the axillary lymph nodes, with non-invasive breast residuals permitted, including ductal carcinoma in situ (ypT0/is ypN0) according to the 7th Edition of AJCC Cancer Staging Manual.14
Two hundred and sixty-one patients received a median of 8 cycles of neoadjuvant chemotherapy (interquartile range, 6-8; range, 4 to 16 cycles). Treatment options were determined by molecular subtype, clinical stage, risk factors combined with full underlying evaluation for all patients, among whom, 44 patients were treated with anthracycline-based regimen only, such as CAF (cyclophosphamide, anthracyclines, and 5-fluorouracil), and AC (anthracycline, and cyclophosphamide); 106 patients were treated with taxane-based regimen only; for instance, TP (taxane, and carboplatin), and XT (capecitabine, and taxane); 111 patients were treated with combination regimens of anthracycline and taxane, including AT (anthracycline, and taxane), AC-T (anthracycline, and cyclophosphamide followed by taxane), and TAC (taxane, anthracycline, and cyclophosphamide). Patients with HER2 overexpression were recommended additional trastuzumab-targeted therapy.
The relative dose intensity was calculated according to the standard dose of different chemotherapeutics in the 2008 National Comprehensive Cancer Network (NCCN) guidelines.12
SPSS 16.0 software (SPSS Inc., Chicago, IL) was used to perform analysis. Categorical variables were described by percentage. The association of baseline characteristics with pathological response was analysed using Pearson’s χ2 test. Factors achieving p<0.1 in univariate analysis were set as alternative variables, and unconditional logistic regression model was applied to determine whether a factor was independent predictor of pCR in multivariate analysis. Besides, chemotherapy cycle was also set as alternative variables according to the suggestion of oncologist in our department. Bivariate correlation was used to explore the correlation coefficient of ER and PgR, thereafter hormone receptor (HR) was used for replacement of ER and PgR. Thus, a total of 10 factors were included in the original regression model. Backward conditional method was used to filter variables, OR was calculated by the ratio of number of cases reached pCR divided by number of cases hadn’t reached pCR for patients with and without administration of trastuzumab. All statistical tests were two-sided, and statistical significance was defined as a p-value<0.05.
RESULTS
Two hundred and sixty-one operable primary breast cancer patients were included in this study. Patient characteristics were listed in Table I.
After completion of NAC, 29.1% of breast tumors achieved pCR. The pCR rate differed significantly among different breast cancer subtypes (P<0.001). Patients of TN subtype had the highest pCR rate (22/44, 50.0%), followed by HER2-positive (41/104, 39.4%), and the Luminal subtype showed the lowest pCR rate (13/113, 11.5%).
After univariate analysis, patients with smaller tumor size and higher grade were more likely to achieve higher rate of pCR (p=0.020, p <0.001). At the same time, ER- or PgR-negative tumors were more likely to respond to chemotherapy (both p<0.001). However, tumors with HER2-positive had significantly higher pCR rate (p=0.004). Besides, expression of Ki67, status of underlying axillary lymph nodes, and taxane-based regimen were all significantly associated with pCR (p=0.009, p<0.001, p<0.001). Notably, BMI and baseline PLR had nearly significant association with pCR (p=0.093, p=0.054, Table Ⅱ).
Nine factors with p<0.1 in univariate analysis, including BMI, tumor size, grade, HR, HER2, Ki67 index, lymph nodes, chemo-therapy regimens, and baseline PLR, together with chemotherapy cycles, were set as alternative variables, and unconditional logistic regression model was applied to explore independent factor of pCR. Finally, the multivariate analysis revealed that 5 factors were independent favorable predictors of pCR (Table Ⅲ), which were high histological grade, negative HR status and lymph nodes, positive HER2 status, and taxane-based regimens.
A total of 104 patients had HER2-positive tumors, and 43 cases of them received trastuzumab-included NAC regimen, and pCR rate was 62.8% (27/43). On the other hand, the remaining 61 patients received NAC regimen without trastuzumab, and the pCR rate was significantly lower (14/61, 23.0% versus 62.8%, OR=5.67, p <0.001).
DISCUSSION
Neoadjuvant chemotherapy has been widely utilised in treatment of breast cancer, and pathological diagnosis after surgery contri-buted to evaluation of curative effect. Some clinicopathological characteristics and treatment related factors may play essential role in tumor response to preoperative chemotherapy.
Previous researches showed high histological grade and negative hormone receptor status were favourable predictive factors of pCR,15-17 and this study obtained the similar conclusions. Because of the correlation coefficient of ER and PgR had reached 0.773 in this study, multivariate analysis based on HR was conducted, and similar results as previous researches were acquired. However, we failed to demonstrate tumor size as an independent predictive factor of pCR, which ascribed to the relative small sample size of this study compared to studies base on National Cancer Registry.18,19 The expression level of Ki67 as an independent predictive factor of pCR was also failed to be verified,20,21 which may be owing to the association between histological grade and Ki67.22 In this study, the proportion of patients with high expression of Ki67 was significantly higher in grade Ⅲ group (96.7%, 58/60) than that in grade I +Ⅱ group (71.3%, 134/188, p <0.001).
It has been widely recognised that lymph nodes involved after NAC play a key role in the prognosis of breast cancer patients. The response of axilla to NAC is an important component of pathological evaluation. In this study, negative axillary lymph nodes before treatment was proved to be a favourable predictive factor of pCR.
A study conducted in Turkey showed pCR rates in normal/underweight, overweight and obesity were 31.2%, 22.4%, and 17.9% respectively, indicating a considerable trend towards significance; and obesity was an independent adverse predictor of pCR compared with normal/underweight patients.23 As is widely known, the BMI cutoff value for category of obesity extent is different between WHO and Chinese standards.10, 24 In this study, the association between BMI and pCR under the above two standards was investigated respectively, which was found in neither univariate analysis nor multivariate analysis. Same is concluded by two meta-analyses.7,25
Peripheral blood was routinely tested for all breast cancer patients before initiation of treatment, and the association of baseline NLR/PLR and pCR was evaluated in this study. Regardless of the baseline NLR, similar rates of pCR were achieved. Inconsistent to previous research,9 patients with higher baseline PLR (≥150) were more sensitive to NAC, and had corresponding higher pCR rate. So, further research on this field is needed.
Anthracycline-based and taxane-based systematic chemotherapy are both recommended by guidelines. Patients treated with anthracycline-based, taxane-based and combination regimens had accounted for 16.9%, 40.6%, and 42.5%, respectively. Taxane-based regimen showed a better performance in both univariate and multivariate analysis.
NAC combined with targeted therapy was preferred recommendation by guidelines for HER2-positive breast cancer. In this study, chemotherapy response of HER2-positive breast cancer was significantly affected by administration of trastuzumab. However, not every patient can afford administration of trastuzumab at her own expense. Therefore, government policy on medical insurance may also have an impact on the effectiveness of anti-cancer treatment.
The present study has several limitations. Being a retrospective study, histological grade, HER2 status and expression of Ki67 were unknown in 5.0%, 2.7% and 6.5% of the total patients respectively, which might influence the results.
CONCLUSION
The present study demonstrated that breast cancer patients with high histological grade, negative HR status and lymph nodes, positive HER2 status, as well as taxane-based regimens were more likely to achieve pCR. This may help in selection of candidates for NAC. However, extrapolation of the conclusion should be cautious, further research is warranted for verification of our findings.
FUNDING:
Clinical Key Specialist Construction Project of Shunyi District, Beijing (2015QJTS07).
ETHICAL APPROVAL:
The present study was approved prior to initiation of the research work by the Research and Ethical Committee of Shunyi District Health Care Hospital for Women and Children of Beijing, and conducted in accordance with the Principles of Helsinki Declaration (approval No. 2019-01 on 9th October 2019).
PATIENTS’ CONSENT:
As a non-interventional study, a waiver for informed consent was obtained from the Research and Ethical Committee of Shunyi District Health Care Hospital for Women and Children of Beijing, and all the data from patients were analyzed anonymously.
CONFLICT OF INTEREST:
Authors declared no conflict of interest.
AUTHORS’ CONTRIBUTION:
YLv: Contributed to drafting the work, approval of the final version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
YL: Contributed to the conception and design of this work.
WM, HF: Contributed to the interpretation of the data, and critical revision for important intellectual content.
REFERENCES